Abstract
This research will continue the study of the health industry complex (CIS), an array of instruments to align health policy with industrial policy. We began this research a decade ago, and we now aim to expand it to the case of COVID-19. The pandemic has shifted the incentives of biomedical innovation, promoted collaboration among drug regulatory agencies in ways never seen before, and res…